Anterior Uveitis Associated with ASIA Syndrome: A Distinct Clinical Entity?

IF 2.6 4区医学 Q2 OPHTHALMOLOGY

Ocular Immunology and Inflammation Pub Date : 2025-07-10 DOI:10.1080/09273948.2025.2530131

Şule Barman Kakil, Mete Pekdiker, Talip Akikol

{"title":"Anterior Uveitis Associated with ASIA Syndrome: A Distinct Clinical Entity?","authors":"Şule Barman Kakil, Mete Pekdiker, Talip Akikol","doi":"10.1080/09273948.2025.2530131","DOIUrl":null,"url":null,"abstract":"Purpose: To investigate whether anterior uveitis developing after BNT162b2 COVID-19 vaccination-classified as Autoimmune/Inflammatory Syndrome Induced by Adjuvants (ASIA)-exhibits distinct clinical features compared to idiopathic uveitis.Methods: This single-center retrospective study analyzed records of patients diagnosed with non-infectious anterior uveitis between June 1, 2021, and December 31, 2022. Patients were categorized into two groups: post-vaccine ASIA-related uveitis (Group 1) and idiopathic uveitis (Group 2).Results: A total of 62 patients were included: 12 in Group 1 and 50 in Group 2. The mean age was similar (33.8 ± 10.4 vs. 35.1 ± 10.8 years; p = 0.547), with male predominance in both groups (61.1% vs. 58.5%). Group 1 had significantly milder anterior chamber inflammation (1.94 ± 0.64 vs. 2.85 ± 0.94; p < 0.001) and fewer ocular complications (16.7% vs. 60.0%; p = 0.003). All Group 1 cases responded to topical corticosteroids alone, while 32.3% in Group 2 required systemic immunosuppressants (p = 0.004). Best corrected visual acuity improved in both groups over time, but recovery was faster and more complete in Group 1 (p < 0.001 for time × group interaction).Conclusion: Anterior uveitis associated with ASIA syndrome post-vaccination appears to follow a milder, self-limiting course, with better visual outcomes and less aggressive treatment needs than idiopathic uveitis. These findings offer important insight into the clinical behavior of vaccine-associated ocular inflammation.","PeriodicalId":19406,"journal":{"name":"Ocular Immunology and Inflammation","volume":" ","pages":"1-7"},"PeriodicalIF":2.6000,"publicationDate":"2025-07-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Ocular Immunology and Inflammation","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/09273948.2025.2530131","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: To investigate whether anterior uveitis developing after BNT162b2 COVID-19 vaccination-classified as Autoimmune/Inflammatory Syndrome Induced by Adjuvants (ASIA)-exhibits distinct clinical features compared to idiopathic uveitis.

Methods: This single-center retrospective study analyzed records of patients diagnosed with non-infectious anterior uveitis between June 1, 2021, and December 31, 2022. Patients were categorized into two groups: post-vaccine ASIA-related uveitis (Group 1) and idiopathic uveitis (Group 2).

Results: A total of 62 patients were included: 12 in Group 1 and 50 in Group 2. The mean age was similar (33.8 ± 10.4 vs. 35.1 ± 10.8 years; p = 0.547), with male predominance in both groups (61.1% vs. 58.5%). Group 1 had significantly milder anterior chamber inflammation (1.94 ± 0.64 vs. 2.85 ± 0.94; p < 0.001) and fewer ocular complications (16.7% vs. 60.0%; p = 0.003). All Group 1 cases responded to topical corticosteroids alone, while 32.3% in Group 2 required systemic immunosuppressants (p = 0.004). Best corrected visual acuity improved in both groups over time, but recovery was faster and more complete in Group 1 (p < 0.001 for time × group interaction).

Conclusion: Anterior uveitis associated with ASIA syndrome post-vaccination appears to follow a milder, self-limiting course, with better visual outcomes and less aggressive treatment needs than idiopathic uveitis. These findings offer important insight into the clinical behavior of vaccine-associated ocular inflammation.

查看原文本刊更多论文

前葡萄膜炎与亚洲综合征相关：一个独特的临床实体？

目的：探讨BNT162b2 COVID-19疫苗接种后发生的前葡萄膜炎（归类为佐剂诱导的自身免疫/炎症综合征（ASIA））与特发性葡萄膜炎相比是否具有不同的临床特征。方法：本单中心回顾性研究分析了2021年6月1日至2022年12月31日诊断为非感染性前葡萄膜炎的患者记录。患者分为两组：疫苗后亚洲相关性葡萄膜炎（1组）和特发性葡萄膜炎（2组）。结果：共纳入62例患者：1组12例，2组50例。平均年龄相似(33.8±10.4岁vs. 35.1±10.8岁；P = 0.547)，两组均为男性优势（61.1%对58.5%）。1组前房炎症明显减轻(1.94±0.64∶2.85±0.94；p = 0.003)。所有1组病例仅对局部皮质类固醇有反应，而2组中32.3%的患者需要全身免疫抑制剂（p = 0.004）。随着时间的推移，两组的最佳矫正视力都有所改善，但第一组的恢复速度更快，更完全(p)结论：接种疫苗后与亚洲综合征相关的前葡萄膜炎似乎遵循较温和的自限性过程，与特发性葡萄膜炎相比，视力结果更好，治疗需要较少。这些发现为疫苗相关眼部炎症的临床行为提供了重要的见解。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Ocular Immunology and Inflammation 医学-眼科学

CiteScore

6.20

自引率

15.20%

发文量

285

审稿时长

6-12 weeks

期刊介绍： Ocular Immunology & Inflammation ranks 18 out of 59 in the Ophthalmology Category.Ocular Immunology and Inflammation is a peer-reviewed, scientific publication that welcomes the submission of original, previously unpublished manuscripts directed to ophthalmologists and vision scientists. Published bimonthly, the journal provides an international medium for basic and clinical research reports on the ocular inflammatory response and its control by the immune system. The journal publishes original research papers, case reports, reviews, letters to the editor, meeting abstracts, and invited editorials.